Pacific Biosciences of California, Inc.
PACB
NASDAQ·Healthcare·Medical - Devices·Mkt cap $419.3M
$1.35
▲ +3.85%
P/E
-3.14
Mkt Cap
$419.3M
52-Wk Range
$1.07–$2.73
52-Week Range
$1.07 - $2.73
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 8.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary SMRT sequencing technology
- High-precision genetic mapping capabilities
- Comprehensive genomic research solutions
- Strategic partnerships with research institutions
Bear Case
1 risk
- High volatility (beta 2.3). Larger-than-normal price swings expected.
Growth
Stable outlook
Expanding precision medicine market
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Stable
-2.2% over 3m
Quality
Stable
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying PACB right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 3, 2026
AUG 3, 2026
Reported EPS of -$0.14 vs -$0.13 consensus (-9.4% surprise). Revenue of $39.0M vs $42.9M expected (-9.1%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-9.4%
Revenue trend · last 8Q
—
-33%
-4%
+10%
-4%
+14%
+0%
-2%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$40.0M
$39.2M
$37.2M
$39.8M
$38.4M
$44.6M
$37.2M
$39.0M
Margins · last 8Q
Gross
—
Operating
—
Profit
-114.7%
Wall Street consensus
1 analyst · 0% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
0%
Hold
0%
Sell
100%
Median Price Target
—
Latest: Barclays · May 11, 2026
vs Industry
How PACB stacks vs Medical - Devices
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related